Cargando…
Emerging clinical trial designs may accelerate translation in hematology: lessons from COVID-19
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Society of Hematology
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242698/ https://www.ncbi.nlm.nih.gov/pubmed/35764486 http://dx.doi.org/10.1182/bloodadvances.2021005963 |
| _version_ | 1784738108429828096 |
|---|---|
| author | Neal, Matthew D. Lawler, Patrick R. Zarychanski, Ryan |
| author_facet | Neal, Matthew D. Lawler, Patrick R. Zarychanski, Ryan |
| author_sort | Neal, Matthew D. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9242698 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | American Society of Hematology |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-92426982022-06-30 Emerging clinical trial designs may accelerate translation in hematology: lessons from COVID-19 Neal, Matthew D. Lawler, Patrick R. Zarychanski, Ryan Blood Adv Commentary American Society of Hematology 2022-08-12 /pmc/articles/PMC9242698/ /pubmed/35764486 http://dx.doi.org/10.1182/bloodadvances.2021005963 Text en © 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. https://www.ncbi.nlm.nih.gov/pmc/pmcdoc/tagging-guidelines/article/tags.html#el-licenseThis article is made available via the PMC Open Access Subset for unrestricted reuse and analyses in any form or by any means with acknowledgment of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections. |
| spellingShingle | Commentary Neal, Matthew D. Lawler, Patrick R. Zarychanski, Ryan Emerging clinical trial designs may accelerate translation in hematology: lessons from COVID-19 |
| title | Emerging clinical trial designs may accelerate translation in hematology: lessons from COVID-19 |
| title_full | Emerging clinical trial designs may accelerate translation in hematology: lessons from COVID-19 |
| title_fullStr | Emerging clinical trial designs may accelerate translation in hematology: lessons from COVID-19 |
| title_full_unstemmed | Emerging clinical trial designs may accelerate translation in hematology: lessons from COVID-19 |
| title_short | Emerging clinical trial designs may accelerate translation in hematology: lessons from COVID-19 |
| title_sort | emerging clinical trial designs may accelerate translation in hematology: lessons from covid-19 |
| topic | Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242698/ https://www.ncbi.nlm.nih.gov/pubmed/35764486 http://dx.doi.org/10.1182/bloodadvances.2021005963 |
| work_keys_str_mv | AT nealmatthewd emergingclinicaltrialdesignsmayacceleratetranslationinhematologylessonsfromcovid19 AT lawlerpatrickr emergingclinicaltrialdesignsmayacceleratetranslationinhematologylessonsfromcovid19 AT zarychanskiryan emergingclinicaltrialdesignsmayacceleratetranslationinhematologylessonsfromcovid19 |